

## Surrey and North West Sussex Area Prescribing Committee (APC)

Policy Statement	AChE inhibitors* or memantine for people with cognitive impairment caused by multiple sclerosis
Policy Number	APC 395 -2019
Date of Issue	March 2019
Review Date:	March 2022 (Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)
<b>Recommendations:</b> The Surrey and North West Sussex Area Prescribing Committee (APC) does not recommend AChE inhibitors* of memantine for people with cognitive impairment caused by multiple sclerosis, in line with NICE guideline (NG97)	
A <b>BLACK</b> traffic light status is recommended for AChE inhibitors & memantine for this indication.	
Key Considerations:	
NICE guideline (NG97) - Dementia: assessment, management and support for people living with dementia and their carers. <u>https://www.nice.org.uk/guidance/ng97/resources/dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109</u>	
*AChE inhibitors – galantamine, rivastigmine & donepezil	
Date taken to Area Prescribing Committee	6 <sup>th</sup> March 2019
Agreed by APC members	22 <sup>nd</sup> March 2019

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG